Copenhagen, Denmark · IncubatorBioInnovation Institute is a life science incubator backed by the Novo Nordisk Foundation that helps researchers and founders turn biotech and health innovations into venture ready companies. Based in Copenhagen, BII provides lab space, grant funding, expert business support, and access to investors for projects in therapeutics, diagnostics, and industrial biotech. It runs programs for both idea stage research and early startups, de risking science heavy ventures before they seek larger capital. BII is a central node in the Danish life science startup pipeline.
IncubatorBiotechHealthtechLife Science
Paris, France · StartupBioptimus is the self-proclaimed "Mistral of Biology," spun out in early 2024 by a team of alumni from Google DeepMind and Owkin, including CEO Jean-Philippe Vert. The company is building what it calls the first universal foundation model for biology. Where large language models were trained on text to learn human language, Bioptimus trains on biological data—DNA sequences, protein structures, cellular imagery, and clinical phenotypes—to infer the underlying rules of life. The ambition is not just better predictions but a unified biological reasoning layer that can simulate outcomes before expensive lab work happens.
By 2026, Bioptimus has moved from a research thesis to early commercial traction. After a $41M Series A in 2025, the company released its first commercial model that can predict how a specific molecule will interact with a human cell with unusually high accuracy. This enables in-silico screening that reduces wet-lab costs and improves hit rates for drug discovery. French pharma leaders such as Sanofi have begun using these models to prioritize compounds and compress early-stage discovery timelines. The product value is immediate: fewer failed experiments, faster candidate selection, and deeper mechanistic insight.
Bioptimus' roadmap focuses on "multi-scale biology," connecting the micro level (genomics and proteomics) to the macro level (patient outcomes and clinical data). Rather than being limited to protein folding, the models aim to bridge across data modalities so a genetic mutation can be linked to disease pathways, tissue behavior, and potential therapeutic interventions. This requires data breadth and regulatory trust, and Bioptimus is building a defensive moat through European data sovereignty. It leverages partnerships with European research hospitals and biobanks to access high-quality patient data that is difficult for US competitors to acquire under GDPR constraints. That compliance burden becomes a competitive advantage: safer access, better provenance, and stronger alignment with European health data governance.
The company remains deeply embedded in the Paris ecosystem. It was incubated inside Owkin before spinning out, maintains a presence around Station F, and benefits from the cross-pollination between French AI and biotech communities. Its investor base reflects that positioning: Sofinnova Partners, Bpifrance, Cathay Innovation, Xavier Niel, and Frst provide a blend of life-science expertise, sovereign capital, and deep-tech conviction. In 2026, Bioptimus is the clearest European bet that foundation models can unlock biology at scale—and a contender to become the default AI layer for drug discovery in Europe.
StartupGrowthBiotechAIHealthcare
Copenhagen, Denmark · AcceleratorAccelerace is Denmark's longest-running accelerator and pre-seed investor, founded in 2008 to help early-stage teams validate products, refine go-to-market strategy, and access investors. The program runs multiple tracks across general tech, life science, and sustainability, and pairs founders with a large mentor network. Accelerace also invests small tickets in selected teams and helps them prepare for follow-on funding. It has supported 800+ Nordic startups and remains a core launchpad in the Danish ecosystem.
AcceleratorPre-Seed to SeedGeneral TechLife ScienceSustainability
Lyngby, Denmark · Event OrganisatorOrganizes courses focused on leading the bio-revolution across life science, offering executive education and leadership development for professionals in biotechnology and related fields.
Event OrganisatorBiotechnologyLife ScienceEducationLeadershipEvents
Copenhagen, Denmark · StartupHemab is a clinical-stage biotech company developing prophylactic therapies for severe bleeding and thrombotic disorders. Founded by biotech operators with Novo Nordisk roots, the company engineers antibody-based treatments aimed at preventing episodes before they occur in underserved rare-disease populations.
StartupGrowthBiotechLife SciencesHealthTechPharma
Lyngby, Denmark · EventCourse designed to equip leaders with insights and strategies for navigating and driving innovation in the life science bio-revolution. Focuses on emerging trends and leadership challenges in the sector.
EventBiotechnologyLife ScienceEducationEvents
Loading comments...